WO2016093637A1 - Composition for preventing and improving andropause, comprising carob extract as active ingredient - Google Patents

Composition for preventing and improving andropause, comprising carob extract as active ingredient Download PDF

Info

Publication number
WO2016093637A1
WO2016093637A1 PCT/KR2015/013512 KR2015013512W WO2016093637A1 WO 2016093637 A1 WO2016093637 A1 WO 2016093637A1 KR 2015013512 W KR2015013512 W KR 2015013512W WO 2016093637 A1 WO2016093637 A1 WO 2016093637A1
Authority
WO
WIPO (PCT)
Prior art keywords
symptoms
composition
extract
test
carob extract
Prior art date
Application number
PCT/KR2015/013512
Other languages
French (fr)
Korean (ko)
Inventor
이정민
주세환
Original Assignee
주식회사 엔에스웰니스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엔에스웰니스 filed Critical 주식회사 엔에스웰니스
Priority to JP2017550441A priority Critical patent/JP6430659B2/en
Publication of WO2016093637A1 publication Critical patent/WO2016093637A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L11/00Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S426/00Food or edible material: processes, compositions, and products
    • Y10S426/804Low calorie, low sodium or hypoallergic

Definitions

  • the present invention relates to a new use of the carob extract, and more particularly to a composition for preventing and improving the symptoms appearing in menopausal men, including the carob extract as an active ingredient.
  • menopausal term is a term used to describe various symptoms of female hormone deficiency after menopause, and has no relation to men without menopause.
  • menopause the secretion of androgen decreases, so several symptoms appear.
  • these men are also referred to as menopause and occur mainly in men in their 50s.
  • symptoms include fatigue, memory loss, depression, increased body fat, decreased bone density, erectile dysfunction, and decreased libido. If external factors such as excessive drinking, smoking, and stress are added, these symptoms are further promoted. . Moreover, the majority of older men have adult diseases such as high blood pressure and diabetes, which makes the problem worse.
  • hormone therapy is typically used as a means for treating male menopausal symptoms.
  • Hormone therapy is an artificial replenishment of deficiency of male hormones, and its effect is known to be good.
  • the above treatment is performed solely because it is similar to male menopausal symptoms, it may cause serious side effects. There are many cases of side effects caused by supplementation, which requires accurate diagnosis by experts.
  • Carob is an evergreen broad-leaved shrub belonging to the legume, drought-tolerant, and contains resin in the leaves. There has been no research on the effect of these carobs on menopausal symptoms.
  • the problem to be solved in the present invention is to effectively alleviate the symptoms occurring in menopausal men, it consists of natural ingredients for preventing and improving male menopausal composition comprising a carob extract as an active ingredient that can minimize rejection to the body To provide.
  • composition according to the present invention for solving the above problems is characterized in that it comprises a carob extract as an active ingredient.
  • composition comprising the extract according to the present invention as an active ingredient is prostatic hyperplasia, lower urinary tract symptoms, nervousness, emotional anxiety, depression, hot flashes, sleep disorders, vitality, decreased work ability, decreased sexual desire, which occurs in menopausal men Symptoms such as erectile dysfunction, loss of energy, weakness, loss of motor skills and hair loss can be improved.
  • Figure 4 is a graph showing the rate of improvement of prostate hyperplasia and lower urinary tract symptoms of the test subjects measured by the IPSS test
  • 'extract' is a meaning commonly used in the art as a crude extract (Crude extract), but broadly also includes the meaning of the fraction (Fractionation) additionally extract (Fractionation). That is, the carob extract includes not only those obtained by using the above-described extraction solvent, but also those obtained by additionally applying a purification process thereto.
  • 'including as an active ingredient' means containing an amount sufficient to achieve the efficacy or activity of the carob extract.
  • the present invention is a composition extracted from a carp which is a natural plant material, and there is no side effect to the human body even when an overdose is administered, so that the upper limit of the amount of the carob extract contained in the composition of the present invention can be carried out by a person skilled in the art.
  • 'pharmaceutically effective amount means an amount sufficient to achieve the efficacy or activity of the carob extract.
  • Male menopause is a collective term for several symptoms in middle-aged men, similar to female menopause. External manifestations include fatigue, decreased memory, depression, increased body fat, decreased bone density, erectile dysfunction, decreased libido, lower urinary tract symptoms, Hypogonadism, and internally, testosterone hypoplasia. If external factors such as excessive drinking, smoking and stress are added, the above symptoms are further promoted. Moreover, the majority of older men have adult diseases such as high blood pressure and diabetes, which makes the problem worse.
  • Carob extract according to the present invention is extracted using an organic solvent, which can be used as an extraction solvent is as follows.
  • suitable as polar solvents are (i) water, (ii) alcohols having 1 to 6 carbon atoms (preferably methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol , 2-butoxyethanol or ethylene glycol), (iii) acetic acid, (iv) dimethyl-formamide (DMFO) and (v) dimethyl sulfoxide (DMSO).
  • alcohols having 1 to 6 carbon atoms preferably methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol , 2-butoxyethanol or ethylene glycol
  • acetic acid preferably methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol , 2-butoxyethanol or
  • nonpolar solvents are acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1 -Pentene, 1-chlorobutane, 1-chloropentane, o-xylene, diisopropyl ether, 2-chloropropane, toluene, 1-chloropropane, chlorobenzene, benzene, diethyl ether, diethyl sulfide, chloroform, Dichloromethane, 1,2-dichloroethane, anneal, diethylamine, ether, carbon tetrachloride, methylene chloride, petroleum ether and THF.
  • the present invention is an extraction solvent, (a) water, (b) anhydrous or lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, etc.), (c) a mixed solvent of the lower alcohol and water, (d Acetone, (e) ethyl acetate, (f) chloroform, (g) butyl acetate, (h) 1,3-butylene glycol, (i) hexane and (j) diethyl ether, and the like. It is more preferable to extract water, ethanol or a mixture of water and ethanol in a carob for easy extraction.
  • the carob extract used in the present invention may be prepared in a powder state by an additional process such as distillation under reduced pressure and freeze drying or spray drying.
  • the present invention can be used to extract the extract using the above extraction solvent, the following describes a method for producing a carob extract.
  • Carp extract to be used in the experiment to be described later the first extraction by hot water extraction method for 4 hours using a purified water of 8 times the weight of the crushed powder of carob fruit as a solvent, the second extraction by adding 4 times purified water, the extract The mixture was filtered with a filter cloth, concentrated in vacuo, and then prepared by spray drying by mixing the extract with dextrin in a 1: 1 ratio.
  • the carob extract may be prepared by a subcritical extraction method using a subcritical fluid or a supercritical extraction method using a supercritical fluid.
  • conditions for breeding were provided at a temperature of 24 ⁇ 2 ° C., a humidity of 50 to 55%, and water and diet.
  • composition of the present invention By confirming the effect of the composition of the present invention on the weight gain was confirmed whether it is effective in preventing or treating menopausal menopause.
  • Body weight was measured at the same time on the test start date and the end date of each group classified in the ⁇ 1-1> test subjects, and the increase was used as a result. The results are shown in FIG. To verify the significance of the test results, the statistical program Student's t-test was used for statistical processing, and it was considered as significant at p ⁇ 0.05.
  • the weight gain of the control group (CTL) ingesting only saline was about 103g
  • the weight gain of the experimental group (CA) ingesting Carob extract was about 84g. It was confirmed that it was significantly low. This shows that carob extract has the effect of inhibiting weight gain, one of the menopausal symptoms.
  • each group classified in the ⁇ 1-1> test subjects was fasted for 8 hours after the last oral administration, followed by ether anesthesia, laparotomy to separate visceral fat, and the weight thereof was measured.
  • the result was converted to the weight of the visceral fat of the control group (CTL) to 100% and the weight of the visceral fat of the experimental group was expressed as a relative ratio value to the control (CTL).
  • CTL control group
  • CTL relative ratio value to the control
  • the visceral fat weight of the experimental group (CA) ingesting the caprope extract was about 66% of the visceral fat weight of the control group (CTL) ingesting only saline. This shows that carob extract has the effect of reducing the increase in visceral fat, one of menopausal symptoms.
  • each group classified in the ⁇ 1-1> test subjects was fasted for 8 hours at the time before oral administration and at the time of the last oral administration, followed by ether anesthesia, and laparotomy to collect blood from the abdominal vein.
  • the blood collected before and after oral administration was transferred to heparin-treated tubes, and centrifuged (2,500 rpm, 15 min, 4 ° C.) to separate plasma.
  • the total testosterone content in blood was measured using an immunoassay kit (R & D Systems, USA). The results are expressed as plasma testosterone content before administration.
  • the results are shown in FIG. 3, and statistically processed using the Student's t-test to verify the significance of the test results, and were considered to be significant at p ⁇ 0.05.
  • I-PSS International Prostate symptom score
  • the results of calculating the IPSS score improvement rate before and after ingestion are shown in FIG. 4.
  • the results were statistically analyzed with the statistical program SPSS (version 12.0) to verify the significance at p ⁇ 0.05 level.
  • the control group (Placebo) had an IPSS score changed by about 2.8%
  • the carob extract intake group (experimental group) had an IPSS score reduced by about 48% or more, thereby effectively improving the prostate enlargement and lower urinary tract symptoms. It became.
  • the carob extract of the composition of the present invention is effective in improving the prostate hypertrophy and lower urinary tract symptoms that may appear in the menopausal period.
  • AMS grades developed in German by Heinemann et al. (Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C. A New 'Aging Male's Symptom' (AMS) Scale.The Aging Male 1992, 2: 105-114.)
  • the validity and reliability of the Korean version of Kim Se-hyun's translation was proved to be valid and reliable in 2003, designed to objectively assess the effect of males on the quality of life of men (Daig I, Heinemann LA, Kim S, Leungwattanakij S, Badia X, Myon E, et al.e Aging Males' Symptoms (AMS) scale: review of its methodological characteristics.Health Qual Life Outcomes 2003; 1: 77.).
  • the Korean version of AMS consists of 17 questions as shown in Table 2, and all items are quantified as no symptoms (1 point), light (2 points), moderate (3 points), severe (4 points), and very severe (5 points). do. A total score of 27 or more is considered as positive.No 17-26 (No), 27-36 (Little), 37-49 (Moderate) and 50 or more severe Separate with (Severe).
  • Each of the 17 AMS questions was classified according to the symptom, and the questionnaire was analyzed for symptoms of nervousness, emotional anxiety, depression, hot flashes, sleep disorders, reduced vitality, decreased work ability, decreased libido, impotence, decreased energy, and stamina. It can be categorized and evaluated as deterioration, motor loss, and hair loss.
  • AMS results of the control group and the experimental group are shown in Table 3 and FIG. 5 as itemized improvement rate and overall improvement rate, and the result values are written as mean and standard deviation, and statistically processed by Student's t-test. Was considered significant at p ⁇ 0.05.
  • the control group's AMS score was not significantly different before and after ingestion, whereas the group receiving the composition showed an improvement in male menopausal symptoms by about 57% or more in the AMS score compared to before the intake.
  • the symptom improvement rate of each item it was confirmed that the symptoms corresponding to each item were improved as a whole.
  • the carob extract alleviated various menopausal symptoms in middle-aged men.
  • the Korean version of the ADAM test paper was Kim Soo-woong ⁇ Kim Soo-woong, Oh Seung-jun, Baek Jae-seung, Kim Se-cheol. Development of a Korean translation of the Androgen Deficiency in Aging Males (ADAM) questionnaire.
  • ADAM Androgen Deficiency in Aging Males
  • Korean Journal of Urology 2004, 45 (7): 674-679. ⁇ Is a Korean version of the Korean version of the Korean version of the Korean version for the purpose of screening male menopausal patients.
  • Ten questions in ADAM can answer yes or no for each symptom, and can test for male hormone deficiency by evaluating sexual dysfunction or other symptoms. If you answered 'yes' to questions 1 or 7 in the test items, or if you answered 3 or more 'yes' to items other than questions 1 and 7, you may be considered to have male menopausal symptoms because of a testosterone deficiency.
  • the ADAM results of the experimental group and the placebo-controlled group ingesting the Carob extract were expressed as the percentage of men suspected of having a male menopausal prevalence (%) based on the test sheet in Table 4.
  • the prevalence of menopausal age before and after ingestion of the experimental and control groups is shown in Table 5, and the results are listed as mean and standard deviation, and statistically treated by Student's t-test at p ⁇ 0.05. Considered significant. (* p ⁇ 0.05 vs. before intake)
  • the control group showed no significant change in the premenstrual prevalence rate before and after placebo intake, whereas the experimental group who consumed the carob composition showed a 38% reduction in premenstrual prevalence after the ADAM test. Therefore, it can be seen that the composition of the present invention improves male menopausal symptoms by alleviating male hormone deficiency.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agronomy & Crop Science (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to a composition for preventing and improving andropause, comprising a carob extract as an active ingredient. Thereby, the present invention can improve symptoms which appear in men with andropause, such as prostatism, lower urinary tract symptoms, nervousness, mental instability, depression, facial blushing, sleep disorders, hypodynamia, reduction in job performance, loss of sexual desire, impotence, decline in stamina, deterioration of physical strength, reduction in exercise ability, and reduction of body hair.

Description

캐롭 추출물을 유효성분으로 포함하는 남성 갱년기 예방 및 개선용 조성물Male menopausal prevention and improvement composition comprising carob extract as an active ingredient
본 발명은 캐롭 추출물의 새로운 용도에 관한 것으로, 더욱 상세하게는 캐롭 추출물을 유효성분으로 포함하여 갱년기 남성에게서 나타나는 증상을 예방 및 개선하기 위한 조성물에 관한 것이다.The present invention relates to a new use of the carob extract, and more particularly to a composition for preventing and improving the symptoms appearing in menopausal men, including the carob extract as an active ingredient.
일반적으로 갱년기는 여성의 폐경 이후에 여성 호르몬 부족으로 나타나는 각종 증상들이 발생하는 시기를 일컫는 용어로서, 폐경이 발생하지 않는 남성과는 무관했다. 그러나 남성 역시 나이가 들어감에 따라 남성 호르몬의 분비가 감소하기 때문에 이와 관련된 여러 증상들이 나타나는데, 근래에는 이러한 남성 역시 갱년기라 지칭하고, 주로 50대 남성에게서 발생한다.In general, menopausal term is a term used to describe various symptoms of female hormone deficiency after menopause, and has no relation to men without menopause. However, as men also age, the secretion of androgen decreases, so several symptoms appear. In recent years, these men are also referred to as menopause and occur mainly in men in their 50s.
남성 갱년기의 경우, 피로감, 기억력 저하, 우울증, 체지방 증가, 골밀도 감소, 발기부전, 성욕저하증 등과 같은 증상이 나타나는데, 만약 과도한 음주와 흡연, 스트레스 등의 외적인 요소가 부가된다면 위와 같은 증상들이 더욱 촉진된다. 더욱이 고령의 남성의 경우 대다수가 고혈압이나 당뇨와 같은 성인병이 있어 문제는 더욱 심각해진다.In menopausal men, symptoms include fatigue, memory loss, depression, increased body fat, decreased bone density, erectile dysfunction, and decreased libido. If external factors such as excessive drinking, smoking, and stress are added, these symptoms are further promoted. . Moreover, the majority of older men have adult diseases such as high blood pressure and diabetes, which makes the problem worse.
한편, 남성 갱년기 증상을 치료하기 위한 수단으로는 대표적으로 호르몬 요법이 쓰이고 있다. 호르몬 요법은 부족한 남성 호르몬을 인위적으로 보충해주는 요법으로서, 그 효과가 좋은 것으로 알려져 있으나, 만약 남성 갱년기 증상과 유사하다는 이유만으로 위 치료방법을 시행할 경우 심각한 부작용을 초래할 수 있고, 또한 신체 특성상 인위적인 호르몬 보충으로 부작용이 발생한 사례가 많아 그 사용에 있어 전문가의 정확한 진단이 요구된다.Meanwhile, hormone therapy is typically used as a means for treating male menopausal symptoms. Hormone therapy is an artificial replenishment of deficiency of male hormones, and its effect is known to be good. However, if the above treatment is performed solely because it is similar to male menopausal symptoms, it may cause serious side effects. There are many cases of side effects caused by supplementation, which requires accurate diagnosis by experts.
따라서 남성 호르몬의 감소로 인한 증상을 치료하거나 예방할 수 있고, 부작용을 최소화시키는 천연 물질을 이용한 조성물에 대한 연구 및 개발이 필요한데, 본 발명자들은 남성 호르몬 조절 이상 증후군 및 이로 인한 증상의 개선 효능이 뛰어난 새로운 천연성분에 관하여 연구하던 중 캐롭{Ceratonia siliqua (L.) Taub.} 추출물이 남성의 갱년기로 인한 증상을 개선하는 것을 확인하여 본 발명을 완성했다.Therefore, there is a need for research and development of compositions using natural substances that can treat or prevent symptoms caused by a decrease in testosterone and minimize side effects. While researching natural ingredients Carrot { Ceratonia siliqua (L.) Taub.} Extract was confirmed to improve the symptoms caused by menopausal men and completed the present invention.
캐롭은 콩과에 속하는 상록 활엽 관목으로, 가뭄에 잘 견디며, 잎에 수지를 함유하고 있다. 이러한 캐롭이 남성의 갱년기 증상과 관련하여 어떠한 효과가 있는지에 대하여는 연구된 바가 없다.Carob is an evergreen broad-leaved shrub belonging to the legume, drought-tolerant, and contains resin in the leaves. There has been no research on the effect of these carobs on menopausal symptoms.
본 발명에서 해결하고자 하는 과제는 갱년기 남성에서 발생하는 증상을 효과적으로 완화시킬 수 있고, 천연성분으로 이루어져 신체에 거부반응을 최소화시킬 수 있는 캐롭 추출물을 유효성분으로 포함하는 남성 갱년기 예방 및 개선용 조성물을 제공하는 것이다.The problem to be solved in the present invention is to effectively alleviate the symptoms occurring in menopausal men, it consists of natural ingredients for preventing and improving male menopausal composition comprising a carob extract as an active ingredient that can minimize rejection to the body To provide.
위와 같은 과제를 해결하기 위한 본 발명에 따른 조성물은 캐롭 추출물을 유효성분으로 포함하는 것을 기술적 특징으로 한다.The composition according to the present invention for solving the above problems is characterized in that it comprises a carob extract as an active ingredient.
본 발명에 따른 캐롭 추출물을 유효성분으로 포함하는 조성물은 갱년기 남성에게서 발생하는 전립선 비대증, 하부요로증상, 신경과민, 정서불안, 우울증, 안면홍조, 수면장애, 활력저하, 업무능력감소, 성욕감퇴, 발기부전, 정력감소, 체력저하, 운동능력감소, 체모감소와 같은 증상들을 개선시킬 수 있다.The composition comprising the extract according to the present invention as an active ingredient is prostatic hyperplasia, lower urinary tract symptoms, nervousness, emotional anxiety, depression, hot flashes, sleep disorders, vitality, decreased work ability, decreased sexual desire, which occurs in menopausal men Symptoms such as erectile dysfunction, loss of energy, weakness, loss of motor skills and hair loss can be improved.
도 1은 시험대상동물의 체중 증가량 측정 결과를 나타낸 그래프1 is a graph showing the measurement results of the weight gain of the test animal
도 2는 시험대상동물의 내장지방 무게 측정 결과를 나타낸 그래프2 is a graph showing the result of measuring the visceral fat weight of the test animal
도 3은 혈중 테스토스테론 농도 측정 결과를 나타낸 그래프3 is a graph showing the results of blood testosterone concentration measurement
도 4는 IPSS 검사법으로 측정된 시험대상남성의 전립선 비대증 및 하부요로증상 개선율을 나타낸 그래프Figure 4 is a graph showing the rate of improvement of prostate hyperplasia and lower urinary tract symptoms of the test subjects measured by the IPSS test
도 5는 AMS 검사법으로 측정된 시험대상남성의 갱년기 증상 개선율을 나타낸 그래프 5 is a graph showing the improvement rate of menopausal symptoms of test subjects measured by AMS test method
본 발명을 설명하기에 앞서 본 발명에서 사용되는 용어의 의미를 설명한다.Before describing the present invention, the meaning of the terms used in the present invention will be explained.
본 명세서에서 '추출물'은 당업계에서 조추출물(Crude extract)로 통용되는 의미이지만, 광의적으로는 추출물을 추가적으로 분획(Fractionation)한 분획물의 의미도 포함한다. 즉, 캐롭 추출물은 상술한 추출용매를 이용하여 얻은 것뿐만 아니라, 여기에 정제과정을 추가적으로 적용하여 얻은 것도 포함한다. 예를 들어, 상기 추출물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 분획, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 캐롭 추출물에 포함되는 것이다.In the present specification, 'extract' is a meaning commonly used in the art as a crude extract (Crude extract), but broadly also includes the meaning of the fraction (Fractionation) additionally extract (Fractionation). That is, the carob extract includes not only those obtained by using the above-described extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, the fraction obtained by passing the extract through an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) Fractions obtained through various purification methods are also included in the carob extract of the present invention.
본 명세서에서 '유효성분으로 포함하는'이란 캐롭 추출물의 효능이나 활성을 달성하는데 충분한 양을 포함하는 것을 의미한다. 본 발명은 천연식물재료인 캐롭으로부터 추출한 조성물로서, 과량 투여하여도 인체에 부작용이 없으므로 캐롭 추출물이 본 발명의 조성물에 포함된 양적 상한은 통상의 기술자가 적절한 범위 내에서 선택하여 실시할 수 있다.In the present specification, 'including as an active ingredient' means containing an amount sufficient to achieve the efficacy or activity of the carob extract. The present invention is a composition extracted from a carp which is a natural plant material, and there is no side effect to the human body even when an overdose is administered, so that the upper limit of the amount of the carob extract contained in the composition of the present invention can be carried out by a person skilled in the art.
본 명세서에서 '약학적 유효량'은 캐롭 추출물의 효능 또는 활성을 달성하는 데 충분한 양을 의미한다.As used herein, 'pharmaceutically effective amount' means an amount sufficient to achieve the efficacy or activity of the carob extract.
남성 갱년기는 여성 갱년기와 유사하게 중년의 남성에게서 나타나는 여러 증상들을 통칭하는 것으로, 외부적으로 나타나는 증상으로는 피로감, 기억력 저하, 우울증, 체지방 증가, 골밀도 감소, 발기부전, 성욕저하증, 하부요로증상, 성선기능저하증 등이 있으며, 내부적으로는 테스토스테론 저하증이 있다. 만약 과도한 음주와 흡연, 스트레스 등의 외적인 요소가 부가된다면 위와 같은 증상들이 더욱 촉진된다. 더욱이 고령의 남성의 경우 대다수가 고혈압이나 당뇨와 같은 성인병이 있어 문제는 더욱 심각해진다.Male menopause is a collective term for several symptoms in middle-aged men, similar to female menopause. External manifestations include fatigue, decreased memory, depression, increased body fat, decreased bone density, erectile dysfunction, decreased libido, lower urinary tract symptoms, Hypogonadism, and internally, testosterone hypoplasia. If external factors such as excessive drinking, smoking and stress are added, the above symptoms are further promoted. Moreover, the majority of older men have adult diseases such as high blood pressure and diabetes, which makes the problem worse.
아래에서는 이와 같은 남성 갱년기를 완화시키기 위한 캐롭 추출물에 대해 상세히 설명한다.Below is a detailed description of the carob extract for relieving such menopausal age.
본 발명에 따른 캐롭 추출물은 유기용매를 이용하여 추출하는데, 추출용매로서 사용될 수 있는 것은 아래와 같다.Carob extract according to the present invention is extracted using an organic solvent, which can be used as an extraction solvent is as follows.
우선 극성 용매로서 적합한 것은, (i) 물, (ii) 탄소수 1 내지 6의 알코올(바람직하게는, 메탄올, 에탄올, 프로판올, 부탄올, 노말-프로판올, 이소-프로판올, 노말-부탄올, 1-펜탄올, 2-부톡시에탄올 또는 에틸렌글리콜), (iii) 아세트산, (iv) DMFO(Dimethyl-formamide) 및 (v) DMSO(Dimethyl sulfoxide) 등이 있다.Firstly suitable as polar solvents are (i) water, (ii) alcohols having 1 to 6 carbon atoms (preferably methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol , 2-butoxyethanol or ethylene glycol), (iii) acetic acid, (iv) dimethyl-formamide (DMFO) and (v) dimethyl sulfoxide (DMSO).
그리고 비극성 용매로서 적합한 것은, 아세톤, 아세토나이트릴, 에틸 아세테이트, 메틸 아세테이트, 플루오로알칸, 펜탄, 헥산, 2,2,4-트리메틸펜탄, 데칸, 시클로헥산, 시클로펜탄, 디이소부틸렌, 1-펜텐, 1-클로로부탄, 1-클로로펜탄, o-자일렌, 디이소프로필 에테르, 2-클로로프로판, 톨루엔, 1-클로로프로판, 클로로벤젠, 벤젠, 디에틸 에테르, 디에틸 설파이드, 클로로포름, 디클로로메탄, 1,2-디클로로에탄, 어닐린, 디에틸아민, 에테르, 사염화탄소, 메틸렌클로라이드, 석유에테르 및 THF 등이 있다.And nonpolar solvents are acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1 -Pentene, 1-chlorobutane, 1-chloropentane, o-xylene, diisopropyl ether, 2-chloropropane, toluene, 1-chloropropane, chlorobenzene, benzene, diethyl ether, diethyl sulfide, chloroform, Dichloromethane, 1,2-dichloroethane, anneal, diethylamine, ether, carbon tetrachloride, methylene chloride, petroleum ether and THF.
본 발명은 추출용매로서, (a) 물, (b) 탄소수 1 내지 4의 무수 또는 저급 알코올(메탄올, 에탄올, 프로판올, 부탄올 등), (c) 상기 저급 알코올과 물과의 혼합용매, (d) 아세톤, (e) 에틸 아세테이트, (f) 클로로포름, (g) 부틸아세테이트, (h) 1,3-부틸렌글리콜, (i) 헥산 및 (j) 디에틸에테르 등을 사용하는 것이 바람직한데, 용이한 추출을 위해 물, 에탄올 또는 물과 에탄올의 혼합물을 캐롭에 처리하여 추출하는 것이 더욱 바람직하다.The present invention is an extraction solvent, (a) water, (b) anhydrous or lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, etc.), (c) a mixed solvent of the lower alcohol and water, (d Acetone, (e) ethyl acetate, (f) chloroform, (g) butyl acetate, (h) 1,3-butylene glycol, (i) hexane and (j) diethyl ether, and the like. It is more preferable to extract water, ethanol or a mixture of water and ethanol in a carob for easy extraction.
또한, 본 발명에서 이용되는 캐롭 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.In addition, the carob extract used in the present invention may be prepared in a powder state by an additional process such as distillation under reduced pressure and freeze drying or spray drying.
따라서, 본 발명은 위와 같은 추출용매를 이용하여 추출물을 제조할 수 있는데, 아래에서는 캐롭 추출물을 제조하는 방법을 설명한다.Therefore, the present invention can be used to extract the extract using the above extraction solvent, the following describes a method for producing a carob extract.
1)캐롭 추출물의 제조1) Preparation of Carob Extract
①캐롭을 선별하여 분쇄한 뒤, ②분쇄물 중량의 약 1 내지 25배의 부피량(v/w%), 바람직하게는 7 내지 20배의 부피량의 정제수를 포함한 물, 메탄올, 에탄올, 부탄올 등의 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로부터 선택된 용매, 더 바람직하게는 물, 에탄올 또는 이들의 혼합용매로, ③0 내지 120℃, 바람직하게는 50 내지 100℃의 추출온도에서, ④약 1시간 내지 10일, 바람직하게는 약 2시간 내지 8시간 동안, ⑤냉침추출, 열수추출, 초음파 추출, 환류냉각 추출 또는 가열추출법 등의 추출방법으로, 바람직하게는 열수추출 또는 환류냉각 추출법으로 ⑥약 1 내지 10회, 바람직하게는 2 내지 8회 반복 추출한다. 그리고 ⑦상기 추출물을 여과포로 여과하고, ⑧여과액을 진공농축한 후 ⑨-①동결 건조하거나, ⑨-②배합비율에 따라 덱스트린을 혼합하여 분무 건조하여 캐롭 추출물을 획득한다.① After sorting and pulverizing the carp ② Water, methanol, ethanol, butanol containing about 1 to 25 times the volume (v / w%), preferably 7 to 20 times the volume of purified water A solvent selected from a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, more preferably water, ethanol or a mixed solvent thereof, at an extraction temperature of 0 to 120 캜, preferably 50 to 100 캜, For about 1 hour to 10 days, preferably about 2 hours to 8 hours, ⑤ extraction method such as cold needle extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction or heat extraction method, preferably by hot water extraction or reflux cooling extraction method (6) Repeated extraction about 1 to 10 times, preferably 2 to 8 times. And ⑦ the extract is filtered with a filter cloth, ⑧ the filtrate is concentrated in vacuo and then ⑨-① freeze-dried, or IX-x mixed by dextrin according to the mixing ratio to obtain a carob extract.
그리고 후술할 실험에서 사용될 캐롭 추출물은, 캐롭 열매의 분쇄물 중량 8배의 부피량의 정제수를 용매로 하여 4시간 동안 열수추출법으로 1차 추출하고, 4배의 정제수를 가하여 2차 추출한 뒤, 추출물을 여과포로 여과하고, 진공농축한 후 추출물과 덱스트린을 1:1로 혼합하여 분무 건조함으로써 제조한다.Carp extract to be used in the experiment to be described later, the first extraction by hot water extraction method for 4 hours using a purified water of 8 times the weight of the crushed powder of carob fruit as a solvent, the second extraction by adding 4 times purified water, the extract The mixture was filtered with a filter cloth, concentrated in vacuo, and then prepared by spray drying by mixing the extract with dextrin in a 1: 1 ratio.
한편, 캐롭 추출물은 아임계 유체를 이용하여 추출하는 아임계 추출법이나 초임계 유체를 이용하여 추출하는 초임계 추출법을 통해 추출물을 제조하여도 무방하다.Meanwhile, the carob extract may be prepared by a subcritical extraction method using a subcritical fluid or a supercritical extraction method using a supercritical fluid.
아래에서는 본 발명에 따른 캐롭 추출물에 의한 효과를 시험예에 의해 상세히 설명한다.In the following the effect by the carob extract according to the present invention will be described in detail by the test example.
시험예 1: 동물대상시험Test Example 1: Animal Test
<1-1> 시험 대상<1-1> Test subject
10주령, 체중 250g 내외의 스프라그-다우리(Sprague-Dawley) 계통의 웅성 랫트(Rat)를 대조군과 실험군으로 각각 10마리씩 분류하였다. At 10 weeks of age, male rats of Sprague-Dawley strains weighing around 250 g were divided into 10 groups.
실험군은 매일 오전 같은 시간에 50㎎/㎏의 농도로 생리식염수에 녹인 캐롭 추출물을 경구 투여하였고, 대조군은 동일 양의 생리식염수를 경구 투여했다. 참고로, 사육 조건은 온도 24±2℃, 습도 50 내지 55%, 물과 식이는 제한 없이 제공하였다.The experimental group orally administered Carob extract dissolved in physiological saline at a concentration of 50 mg / kg at the same time every morning, the control group was orally administered the same amount of physiological saline. For reference, conditions for breeding were provided at a temperature of 24 ± 2 ° C., a humidity of 50 to 55%, and water and diet.
<1-2> 체중 증가량 측정<1-2> Weight gain measurement
본 발명의 조성물이 체중 증가에 미치는 영향을 확인하여 남성 갱년기 예방 또는 치료에 효과가 있는지를 확인하였다.By confirming the effect of the composition of the present invention on the weight gain was confirmed whether it is effective in preventing or treating menopausal menopause.
체중은 상기 <1-1> 시험 대상에서 분류된 각 군을 시험 시작일과 종료일의 동일한 시간에 체중을 측정하고, 그 증가량을 결과값으로 사용하였다. 결과는 도 1에 도시되어 있다. 시험결과의 유의성 검증을 위해 통계프로그램 스튜던트 t-테스트(Student's t-test)를 이용하여 통계처리 하였고, p<0.05 시에 유의한 것으로 간주하여 표시하였다.Body weight was measured at the same time on the test start date and the end date of each group classified in the <1-1> test subjects, and the increase was used as a result. The results are shown in FIG. To verify the significance of the test results, the statistical program Student's t-test was used for statistical processing, and it was considered as significant at p <0.05.
도 1에 도시된 바와 같이, 생리식염수만 섭취한 대조군(CTL)의 체중 증가량은 약 103g인 반면, 캐롭 추출물을 섭취한 실험군(CA)의 체중 증가량은 약 84g으로 대조군에 비해 체중 증가량이 통계적으로 유의하게 낮은 것을 확인하였다. 이를 통해 캐롭 추출물이 남성 갱년기 증상 중 하나인 체중 증가를 억제하는 효과가 있다는 것을 알 수 있다.As shown in FIG. 1, the weight gain of the control group (CTL) ingesting only saline was about 103g, whereas the weight gain of the experimental group (CA) ingesting Carob extract was about 84g. It was confirmed that it was significantly low. This shows that carob extract has the effect of inhibiting weight gain, one of the menopausal symptoms.
<1-3> 내장지방 무게 측정<1-3> visceral fat weight measurement
본 발명의 조성물이 내장지방 무게에 미치는 영향을 확인하여 남성 갱년기 예방 또는 치료에 효과가 있는지를 확인하였다.Checking the effect of the composition of the present invention on the weight of visceral fat was confirmed whether the effect is effective in preventing or treating menopausal men.
구체적으로, 상기 <1-1> 시험 대상에서 분류된 각 군을 마지막 경구 투여 시점으로부터 8시간 동안 절식시킨 뒤 에테르 마취하고, 개복하여 내장지방을 분리한 다음 그 무게를 측정하였다. 결과값은 대조군(CTL)의 내장지방 무게를 100%로 환산한 뒤 실험군의 내장지방 무게를 대조군(CTL)에 대한 상대 비율 값으로 나타내었다. 결과는 도 2에 도시되어 있으며, 시험결과의 유의성 검증을 위해 통계프로그램 스튜던트 t-테스트(Student's t-test)를 이용하여 통계처리 하였고, p<0.05 시에 유의한 것으로 간주하여 표시하였다.Specifically, each group classified in the <1-1> test subjects was fasted for 8 hours after the last oral administration, followed by ether anesthesia, laparotomy to separate visceral fat, and the weight thereof was measured. The result was converted to the weight of the visceral fat of the control group (CTL) to 100% and the weight of the visceral fat of the experimental group was expressed as a relative ratio value to the control (CTL). The results are shown in FIG. 2, and statistically processed using a statistical program Student's t-test to verify the significance of the test results, and were considered to be significant at p <0.05.
도 2에 도시된 바와 같이, 캐롭 추출물을 섭취한 실험군(CA)의 내장지방 무게는 생리식염수만 섭취한 대조군(CTL)의 내장지방 무게 대비 약 66%로 확인되었다. 이를 통해 캐롭 추출물이 남성 갱년기 증상 중 하나인 내장지방 증가를 감소시키는 효과가 있다는 것을 알 수 있다.As shown in FIG. 2, the visceral fat weight of the experimental group (CA) ingesting the caprope extract was about 66% of the visceral fat weight of the control group (CTL) ingesting only saline. This shows that carob extract has the effect of reducing the increase in visceral fat, one of menopausal symptoms.
<1-4> 체내 테스토스테론 측정<1-4> measurement of testosterone in the body
본 발명의 조성물이 혈중 남성호르몬의 양에 미치는 영향을 확인하여 남성 갱년기 예방 또는 치료에 효과가 있는지를 확인하였다.Checking the effect of the composition of the present invention on the amount of male hormone in the blood to determine whether it is effective in preventing or treating menopausal men.
구체적으로, 상기 <1-1> 시험 대상에서 분류된 각 군을 경구 투여 전 시점과 마지막 경구 투여 시점에서 8시간 동안 절식시킨 뒤 에테르 마취하고, 개복하여 복대정맥으로부터 혈액을 채취하였다. 이렇게 채취된 경구 투여 전과 후의 혈액을 각각 헤파린(Heparin)이 처리된 튜브로 옮긴 뒤 원심분리(2,500rpm, 15min, 4℃)하여 혈장을 분리하였다. 그리고 분리된 혈장에 스테로이드 대체제(Steroid displacement reagent)를 처리한 후, 면역분석 키트(R&D Systems, 미국)를 이용하여 혈중 총 테스토스테론 함량을 측정하였다. 결과값은 투여 전 혈장 테스토스테론 함량 대비 값으로 나타내었다. 결과는 도 3에 도시되어 있으며, 시험결과의 유의성 검증을 위해 통계프로그램 스튜던트 t-테스트(Student's t-test)를 이용하여 통계처리 하였고, p<0.05 시에 유의한 것으로 간주하여 표시하였다.Specifically, each group classified in the <1-1> test subjects was fasted for 8 hours at the time before oral administration and at the time of the last oral administration, followed by ether anesthesia, and laparotomy to collect blood from the abdominal vein. The blood collected before and after oral administration was transferred to heparin-treated tubes, and centrifuged (2,500 rpm, 15 min, 4 ° C.) to separate plasma. After treatment with steroid replacement reagents (Steroid displacement reagent) to the separated plasma, the total testosterone content in blood was measured using an immunoassay kit (R & D Systems, USA). The results are expressed as plasma testosterone content before administration. The results are shown in FIG. 3, and statistically processed using the Student's t-test to verify the significance of the test results, and were considered to be significant at p <0.05.
도 3에 도시된 바와 같이, 생리식염수만 섭취한 대조군(CTL)은 투여 후 통계적으로 유의한 변화가 나타나지 않은 반면, 캐롭 추출물을 섭취한 실험군(CA)은 투여 전에 비해 약 46%의 혈중 테스토스테론 수치가 증가하였다. 이를 통해 캐롭 추출물이 혈중 테스토스테론 농도 증가에 영향을 미친다는 것을 알 수 있다.As shown in Figure 3, the control group ingested only saline (CTL) showed no statistically significant change after administration, whereas the experimental group (CA) ingested Carob extract was about 46% of blood testosterone levels before administration. Increased. This shows that carob extract affects the increase in blood testosterone levels.
시험예 2: 인체대상시험Test Example 2: Human Subject Test
<2-1> 시험 대상<2-1> test object
본 검사에 동의한 만 40세 이상의 남성 30명을 대조군과 실험군으로 각 15명씩 임의로 분류하여 대조군은 위약(Placebo)을 섭취하게 하였고, 실험군은 캐롭 추출물을 일일 40mg씩 4주 동안 섭취하도록 하였다.Thirty males over 40 years of age who agreed to the test were randomly divided into 15 groups of control and experimental groups. The control group received placebo, and the experimental group received 40 mg of carob extract for 4 weeks per day.
<2-2> 전립선증상 점수 설문조사<2-2> Prostate Symptom Score Survey
I-PSS(International Prostate symptom score, 국제전립선증상점수)는 전립선 건강 저하로 인해 나타날 수 있는 하부요로증상 및 그에 따른 삶의 불편함을 객관적으로 평가하기 위해 고안된 검사이다. IPSS는 세계 각국의 언어로 번역되어 타당성이 입증되어 전세계적으로 사용되고 있으며, 국내에서도 검사법의 타당성과 신뢰도가 입증되어 현재 우리나라의 전립선 건강 평가에 사용되는 대표적인 검사법으로 각 항목은 표 1과 같다.The International Prostate symptom score (I-PSS) is a test designed to objectively assess the lower urinary tract symptoms and consequent life discomforts that may be caused by decreased prostate health. IPSS has been translated into various languages around the world and its validity has been proved and used throughout the world. The validity and reliability of the test method have been proved in Korea, and are the representative test methods currently used for prostate health evaluation in Korea.
표 1
항목 전혀 없음 5회 중 1회 3회 중 1회 2회 중 1회 3회 중 2회 항상
1. 평소 소변을 볼 때 다 보았는데도 소변이 남아 있는 것 같이 느끼는 경우가 있습니까?
2. 평소 소변을 보고 난 후 2시간 이내에 다시 소변을 보는 경우가 있습니까?
3. 평소 소변을 볼 때 소변이 멈추었다가 다시 시작되는 경우가 얼마나 자주 있었습니까?
4. 소변이 마려울 때 소변을 참기 어려운 경우가 있습니까?
5. 소변줄기가 약해지거나 늘어진 경우가 얼마나 자주 있었습니까?
6. 평소 소변을 볼 때 힘을 줘야 하거나 기다려야 하는 경우가 얼마나 자주 있었습니까?
없다 1회 2회 3회 4회 5회
7. 평소에 잠을 자다가 일어나서 소변을 보는 경우가 하룻밤에 몇 번이나 있습니까?
매우만족 만족 대체로 만족 반반 대체로 불만족 불행함 끔찍함
만약 지금과 같은 배뇨증상이 지속 된다면 당신은 이것을 어떻게 생각하십니까?
Table 1
Item None at all 1 out of 5 1 of 3 1 of 2 2 of 3 always
1. Do you sometimes feel like urine remains after you have seen it?
2. Do you usually urinate again within 2 hours after you urinate?
3. How often have you stopped and resumed when you urinate?
4. Is it difficult to hold urine when you are urinating?
5. How often have the urine stems become weak or limp?
6. How often have you had to be energized or waited to urinate?
none 1 time Episode 2 3rd time 4 times 5 times
7. How many times per night do you wake up and urinate?
very good satisfied Generally satisfied Half and a half Mostly dissatisfied Unhappy cruelty
What do you think of this if the symptoms of urination persist?
섭취 전과 후의 IPSS 점수 개선율이 계산된 결과가 도 4에 도시되어 있다. 결과는 통계프로그램 SPSS(version 12.0)로 통계 처리하여 p<0.05 수준으로 유의성을 검증하였다.The results of calculating the IPSS score improvement rate before and after ingestion are shown in FIG. 4. The results were statistically analyzed with the statistical program SPSS (version 12.0) to verify the significance at p <0.05 level.
도 4에 도시된 바와 같이 대조군(Placebo)은 IPSS 점수가 2.8% 가량 변화한 반면, 캐롭 추출물 섭취군(실험군)은 IPSS 점수가 약 48% 이상 감소되어 전립선 비대증과 하부요로증상이 효과적으로 개선됨이 확인되었다. 이로써 본 발명의 조성물인 캐롭 추출물이 남성 갱년기에서 나타날 수 있는 전립선 비대증, 하부요로증상 개선에 효과가 있음을 알 수 있다.As shown in FIG. 4, the control group (Placebo) had an IPSS score changed by about 2.8%, while the carob extract intake group (experimental group) had an IPSS score reduced by about 48% or more, thereby effectively improving the prostate enlargement and lower urinary tract symptoms. It became. This can be seen that the carob extract of the composition of the present invention is effective in improving the prostate hypertrophy and lower urinary tract symptoms that may appear in the menopausal period.
<2-3> 한글판 AMS(Aging Males' Symptom)<2-3> Korean Version of Aging Males' Symptom
1999년 Heinemann 등(Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C. A New 'Aging Male's Symptom'(AMS) Scale. The Aging Male 1992, 2:105-114.)이 독일어로 개발한 AMS 등급은 노화가 남성의 삶의 질에 미치는 영향을 객관적으로 평가하기 위해 고안된, 타당도와 신뢰도가 입증된 도구로, 한국판은 2003년 김세현의 번역판이 타당도와 신뢰도가 입증되었다(Daig I, Heinemann LA, Kim S, Leungwattanakij S, Badia X, Myon E, et al. e Aging Males' Symptoms (AMS) scale: review of its methodological characteristics. Health Qual Life Outcomes 2003;1:77.). 한글판 AMS는 표 2와 같이 전체 17개의 문항으로 이루어져 있으며 모든 항목은 증상 없음(1점), 가벼움(2점), 보통(3점), 심함(4점) 및 매우 심함(5점)으로 정량화된다. 총점 27점 이상인 경우를 양성으로 판정하며, 증상 정도에 따라 17-26점은 없음(No), 27-36점은 경도(Little), 37-49점은 중등도(Moderate), 50점 이상을 중증(Severe)으로 구분한다. AMS 17개 문항은 각각 항목에 따라서 증상별로 설문항목을 갱년기의 대표적 증상인 신경과민, 정서불안, 우울증, 안면홍조, 수면장애, 활력저하, 업무능력감소, 성욕감퇴, 발기부전, 정력 감소, 체력저하, 운동능력감소, 체모감소로 분류하여 평가할 수 있다.AMS grades, developed in German by Heinemann et al. (Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C. A New 'Aging Male's Symptom' (AMS) Scale.The Aging Male 1992, 2: 105-114.) The validity and reliability of the Korean version of Kim Se-hyun's translation was proved to be valid and reliable in 2003, designed to objectively assess the effect of males on the quality of life of men (Daig I, Heinemann LA, Kim S, Leungwattanakij S, Badia X, Myon E, et al.e Aging Males' Symptoms (AMS) scale: review of its methodological characteristics.Health Qual Life Outcomes 2003; 1: 77.). The Korean version of AMS consists of 17 questions as shown in Table 2, and all items are quantified as no symptoms (1 point), light (2 points), moderate (3 points), severe (4 points), and very severe (5 points). do. A total score of 27 or more is considered as positive.No 17-26 (No), 27-36 (Little), 37-49 (Moderate) and 50 or more severe Separate with (Severe). Each of the 17 AMS questions was classified according to the symptom, and the questionnaire was analyzed for symptoms of nervousness, emotional anxiety, depression, hot flashes, sleep disorders, reduced vitality, decreased work ability, decreased libido, impotence, decreased energy, and stamina. It can be categorized and evaluated as deterioration, motor loss, and hair loss.
표 2
항목 없음 가벼움 보통 심함 매우심함
1. 몸상태가 안 좋아진 느낌이다.(전반적인 건강에 대한 주관적인 느낌)
2. 관절과 근육이 아프다.(허리, 관절, 등이 아프다거나 팔다리가 쑤신다)
3. 땀이 지나치게 많이 난다.(감자기 식은땀이 나거나 긴장하지 않아도 얼굴이 화끈거린다)
4. 수면장애가 있다.(잠들기 어렵거나, 자다가 자주 깨거나, 아침에 일찍 깨서 피곤하거나, 깊은 잠을 못자거나, 잠을 못 이룬다)
5. 수면시간이 늘지만 그래도 피곤하다.
6. 잘 흥분한다.(공격적이거나, 사소한 일에 쉽게 화를 내거나, 변덕스럽다)
7. 신경이 과민하다.(긴장하거나, 들뜨거나 조바심을 낸다)
8. 항상 불안하다.(전전긍긍한다)
9. 신체적으로 기진맥진하고 활력이 떨어진다.(업무수행능력이 떨어지거나, 활발하지 못하거나, 여가활동에 무관심해지거나, 목표량을 달성하지 못하거나, 기력이 없어서 어떤 일을 억지로 해야만 하는 느낌, 즉 예를 들면 아플 때 일 때문에 직장에 억지로 나가는 느낌이다)
10. 근력이 저하되고 있다.(허약해진 느낌이다)
11. 기분이 우울하다.(기분이 가라앉거나, 슬프거나, 눈물이 맺히거나, 의욕이 없거나, 감정의 변화가 심하거나, 아무 쓸모가 없다고 느껴진다)
12. 전성기가 지나버린 느낌이다.
13. 정서적으로 탈진한 느낌이다.(신체적, 정신적 고갈된 상태로 부정적 태도와 무력감 및 절망감 등을 겪고 있는 느낌이다)
14. 수염이 자라는 속도가 떨어진다.
15. 정력이 떨어지고 성생활 횟수도 줄고 있다.
16. 아침에 발기되는 횟수가 줄고 있다
17. 성욕이 줄고 성적충동도 줄고 있다.(성생활의 즐거움이 없어지거나, 성생활을 하고 싶은 욕망이 없어진다)
TABLE 2
Item none lightness usually Severe Very severe
1. Feeling poorly ill (subjective feeling of overall health)
2. Pain in joints and muscles (sick back, joints, back pain or limb pain)
3. I sweat too much (potatoes are cold even if I don't feel cold)
4. Have trouble sleeping (difficult to sleep, wake up often, sleep early, get tired, can't sleep deep, or can't sleep)
5. I have more sleep but still tired.
6. Excited well (being angry, easily angry, or capricious)
7. My nerves are sensitive (tense, upset or nervous)
8. I'm always anxious.
9. Physically exhausted and lacking energy (a feeling of being forced to do something because of poor performance, lack of activity, indifference to leisure activities, inability to meet targets, or lack of energy, ie For example, when I am sick, I feel like I am forced to go to work.)
10. My strength is falling (I feel weak)
11. I feel depressed (feels calm, sad, tearful, motivated, feelings change, or useless)
12. I feel like my prime is gone.
13. Feeling exhausted emotionally (feeling negative, helpless and hopeless with physical and mental exhaustion)
14. The beard grows slowly.
15. Less energetic and less sexual life.
16. The number of erections in the morning is decreasing
17. Less libido and less sexual impulse (no pleasure in sex life, no desire to live sex life)
대조군 및 실험군의 AMS 결과는 항목별 개선율 및 전체 개선율로 표 3 및 도 5에 도시되어 있고, 결과값은 평균과 표준편차로 기입하였으며, 통계프로그램 스튜던트 t-테스트(Student's t-test)로 통계처리하여 p<0.05 시에 유의한 것으로 간주하였다.The AMS results of the control group and the experimental group are shown in Table 3 and FIG. 5 as itemized improvement rate and overall improvement rate, and the result values are written as mean and standard deviation, and statistically processed by Student's t-test. Was considered significant at p <0.05.
표 3
증상 AMS 문항번호 개선율
대조군 실험군
신경과민 6, 7 5.89% 55.42%
정서불안 8 8.05% 62.96%
우울증 11, 12, 13 9.14% 56.75%
안면홍조 3 7.14% 50.20%
수면장애 4, 5 9.98% 57.78%
활력저하, 업무능력감소 9 2.79% 56.56%
성욕감퇴, 발기부전, 정력감소 15, 16, 17 5.16% 64.54%
체력저하, 운동능력감소 1, 2, 10 1.96% 58.96%
체모감소 14 8.29% 43.85%
총점 - 6.49% 57.51%
TABLE 3
Symptom AMS item number Improvement
Control Experimental group
Nervousness 6, 7 5.89% 55.42%
Anxiety 8 8.05% 62.96%
depression 11, 12, 13 9.14% 56.75%
Hot flashes 3 7.14% 50.20%
Sleep disorder 4, 5 9.98% 57.78%
Decreased vitality, reduced work capacity 9 2.79% 56.56%
Decreased libido, erectile dysfunction, decreased energy 15, 16, 17 5.16% 64.54%
Weakness, reduced motor skills 1, 2, 10 1.96% 58.96%
Hair loss 14 8.29% 43.85%
Total score - 6.49% 57.51%
시험 결과, 대조군의 AMS 점수가 섭취 전후 크게 차이가 없는 반면, 본 조성물 섭취군은 섭취 전에 비해 AMS 점수에서 약 57% 이상의 남성 갱년기 증상 개선율을 보였다. 또한 각 항목별 증상 개선율을 확인한 결과, 각 항목에 해당하는 증상들이 전체적으로 개선되는 것을 확인하였다. 이로써 캐롭 추출물이 중년 남성에서 나타는 다양한 남성갱년기 증상을 전반적으로 완화시킴을 확인하였다.As a result of the test, the control group's AMS score was not significantly different before and after ingestion, whereas the group receiving the composition showed an improvement in male menopausal symptoms by about 57% or more in the AMS score compared to before the intake. In addition, as a result of confirming the symptom improvement rate of each item, it was confirmed that the symptoms corresponding to each item were improved as a whole. As a result, it was confirmed that the carob extract alleviated various menopausal symptoms in middle-aged men.
<2-4> 한글판 ADAM(Androgen Deficiency in Aging Males) <2-4> Androgen Deficiency in Aging Males (ADAM)
2000년 Morley 등(Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000, 49:1239-1242.)이 자신들의 임상경험을 근거로 대표적인 10가지 증상들을 확인하여 남성 호르몬 결핍을 평가하기 위해 개발한 검사지로서 40세 이상의 남성에서 남성호르몬 결핍 상태를 선별할 수 있는 진단검사로서 타당성이 입증되었다. 문항수가 그리 많지 않고, 진단의 민감도가 높아 남성호르몬 결핍 선별검사로 흔히 이용된다. 한글판 ADAM 검사지는 김수웅 등{김수웅, 오승준, 백재승, 김세철. Androgen Deficiency in Aging Males(ADAM) 설문지의 한국어 번역본 개발. 대한비뇨기과학회지 2004, 45(7):674-679.}이 남성 갱년기 환자들을 선별하고 이를 임상연구에 활용할 수 있도록 영어판을 한글판으로 번역한 검사지이다. ADAM의 10개 문항은 각각의 증세에 대해 '예' 또는 '아니오'로 대답할 수 있게 되어있으며, 성기능의 저하 또는 그 밖의 증상 유무를 평가함으로써 남성호르몬 결핍 여부를 평가할 수 있는 검사이다. 검사항목 중 문항 1 또는 7에서 '예'라고 답하거나, 1번과 7번 문항을 제외한 항목에서 3개 이상 '예'라고 답한 경우 남성 호르몬 결핍 증세가 있어 남성갱년기 증세가 있다고 볼 수 있다.Morley et al., 2000 (Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening question naire for androgen deficiency in aging males. Metabolism 2000, 49: 1239-1242.) The test paper was developed to evaluate male hormone deficiency by identifying 10 representative symptoms based on the clinical experience. It has been proved as a valid diagnostic test for screening male hormone deficiency in men over 40 years old. The number of questions is not very high and the sensitivity of diagnosis is high, so it is commonly used for male hormone deficiency screening. The Korean version of the ADAM test paper was Kim Soo-woong {Kim Soo-woong, Oh Seung-jun, Baek Jae-seung, Kim Se-cheol. Development of a Korean translation of the Androgen Deficiency in Aging Males (ADAM) questionnaire. Korean Journal of Urology 2004, 45 (7): 674-679.} Is a Korean version of the Korean version of the Korean version of the Korean version for the purpose of screening male menopausal patients. Ten questions in ADAM can answer yes or no for each symptom, and can test for male hormone deficiency by evaluating sexual dysfunction or other symptoms. If you answered 'yes' to questions 1 or 7 in the test items, or if you answered 3 or more 'yes' to items other than questions 1 and 7, you may be considered to have male menopausal symptoms because of a testosterone deficiency.
표 4
항목 아니오
1. 성욕감퇴가 있습니까?
2. 기력이 있습니까?
3. 체력이나 지구력에 감퇴가 있습니까?
4. 키가 줄었습니까?
5. 삶의 즐거움이 줄었다고 느낀 적이 있습니까?
6. 울적하거나 괜히 짜증이 나십니까?
7. 발기가 예전보다 덜 강합니까?
8. 운동능력이 최근에 떨어진 것을 느낀 적이 있습니까?
9. 저녁 식사 후 바로 잠에 빠져드십니까?
10. 일의 수행능력이 최근에 떨어졌습니까?
Table 4
Item Yes no
1. Is there a decrease in libido?
2. Do you have energy?
3. Do you have a decline in stamina or endurance?
4. Have you reduced your height?
5. Have you ever felt that your joy in life has diminished?
6. Are you crying or irritating?
7. Is erection less intense than before?
8. Have you ever noticed a recent drop in athletic performance?
9. Do you fall asleep right after dinner?
10. Has your performance recently declined?
캐롭 추출물을 섭취한 실험군과 위약을 섭취한 대조군의 ADAM 결과는 표 4의 검사지를 기준으로 남성갱년기 유병률(%)이 의심되는 사람의 비율로 나타내었다. 실험군 및 대조군의 섭취 전과 후의 남성갱년기 유병률은 표 5에 기재되어 있고, 결과값은 평균과 표준편차로 기입하였으며, 통계프로그램 스튜던트 t-테스트(Student's t-test)로 통계처리하여 p<0.05 시에 유의한 것으로 간주하였다. (* p<0.05 vs. 섭취 전)The ADAM results of the experimental group and the placebo-controlled group ingesting the Carob extract were expressed as the percentage of men suspected of having a male menopausal prevalence (%) based on the test sheet in Table 4. The prevalence of menopausal age before and after ingestion of the experimental and control groups is shown in Table 5, and the results are listed as mean and standard deviation, and statistically treated by Student's t-test at p <0.05. Considered significant. (* p <0.05 vs. before intake)
시험 결과, 대조군에서는 위약 섭취 전후 ADAM 검사지로 평가한 남성갱년기 유병률에 큰 변화가 없는 반면, 캐롭 조성물을 섭취한 실험군은 섭취 후 ADAM 검사지로 평가한 남성갱년기 유병률이 약 38% 감소하였다. 따라서 본 발명의 조성물은 남성호르몬 결핍 증세를 완화시켜 남성 갱년기 증상을 호전시킨다는 것을 알 수 있다.As a result, the control group showed no significant change in the premenstrual prevalence rate before and after placebo intake, whereas the experimental group who consumed the carob composition showed a 38% reduction in premenstrual prevalence after the ADAM test. Therefore, it can be seen that the composition of the present invention improves male menopausal symptoms by alleviating male hormone deficiency.
표 5
유병률(%)
섭취 전 섭취 후
대조군 69.8 70.1
실험군 71.2 33.2*
Table 5
Prevalence (%)
Before intake After ingestion
Control 69.8 70.1
Experimental group 71.2 33.2 *

Claims (4)

  1. 캐롭 추출물을 유효성분으로 포함하는 남성 갱년기 증상의 예방 및 개선용 식품 조성물.Food composition for the prevention and improvement of male menopausal symptoms comprising a carob extract as an active ingredient.
  2. 캐롭 추출물을 유효성분으로 포함하는 남성 갱년기 증상의 예방 및 치료용 약학적 조성물.A pharmaceutical composition for preventing and treating male menopausal symptoms, including a carob extract as an active ingredient.
  3. 청구항 1 또는 청구항 2에 있어서,The method according to claim 1 or 2,
    상기 남성 갱년기 증상은 테스토스테론 저하증인 것을 특징으로 하는 조성물.The male menopausal symptom is a testosterone lowering composition.
  4. 청구항 1 또는 청구항 2에 있어서,The method according to claim 1 or 2,
    상기 남성 갱년기 증상은 성선기능저하증, 전립선 비대증, 하부요로증상, 신경과민, 정서불안, 우울증, 안면홍조, 수면장애, 활력저하, 업무능력감소, 성욕감퇴, 발기부전, 정력감소, 체력저하, 운동능력감소, 체모감소 중 어느 하나인 것을 특징으로 하는 조성물.The menopausal symptoms include hypogonadism, prostate hyperplasia, lower urinary tract symptoms, nervousness, emotional anxiety, depression, hot flashes, sleep disorders, vitality, decreased work ability, decreased libido, impotence, stamina, decreased stamina, exercise A composition, characterized in that any one of reduced ability, hair loss.
PCT/KR2015/013512 2014-12-10 2015-12-10 Composition for preventing and improving andropause, comprising carob extract as active ingredient WO2016093637A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017550441A JP6430659B2 (en) 2014-12-10 2015-12-10 A composition for preventing and improving menopause, comprising carob extract as an active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140177696A KR101525948B1 (en) 2014-12-10 2014-12-10 Composition comprising carob extract for preventing, improving menopause of man
KR10-2014-0177696 2014-12-10

Publications (1)

Publication Number Publication Date
WO2016093637A1 true WO2016093637A1 (en) 2016-06-16

Family

ID=53500068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/013512 WO2016093637A1 (en) 2014-12-10 2015-12-10 Composition for preventing and improving andropause, comprising carob extract as active ingredient

Country Status (3)

Country Link
JP (1) JP6430659B2 (en)
KR (1) KR101525948B1 (en)
WO (1) WO2016093637A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102489407B1 (en) * 2021-01-18 2023-01-17 주식회사 네이처센스 COMPOSITION FOR pain relief AND PREVENTING OR ALLEVIATING STRESS-INVOLVED DISEASE COMPRISING Extract of CANNABIS SATIVA L.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102916A (en) * 1990-07-03 1992-04-07 Jacques Antoun Method of relieving gastric ulcers with carob extract
KR20050119134A (en) * 2003-03-21 2005-12-20 넥스메드 홀딩스 인코포레이티드 Prostaglandin compositions for the treatment of erectile dysfunction
US20120282198A1 (en) * 2009-12-24 2012-11-08 Isp Investments Inc. Cosmetic and/or pharmaceutical composition comprising an extract of carob as active agent for activating aquaporin expression
KR20130092499A (en) * 2012-02-10 2013-08-20 주식회사 바이오그랜드 Composition for preventing and improving sex hormone-related disease and symptoms comprising dandelion extract or dandelion containing multiple extract as an active ingredient
KR20140100608A (en) * 2013-02-05 2014-08-18 주식회사 바이오그랜드 Composition for preventing and improving andropause syndrome and aging of male comprising rooibos extract as an active ingredient

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229136A (en) * 1992-05-21 1993-07-20 Clintec Nutrition Co. Low caloric density enteral formulation designed to reduce diarrhea in tube-fed patients
US6763229B2 (en) * 2001-05-02 2004-07-13 Koninklijke Philips Electronics N.V. Timing recovery switching for an adaptive digital broadband beamforming (antenna diversity) for ATSC terrestrial DTV based on segment sync detection
GB0213612D0 (en) * 2002-06-13 2002-07-24 Novartis Nutrition Ag Organic compounds
US9504739B2 (en) * 2011-03-01 2016-11-29 Quorum Innovations, Llc Method of identifying a biologically-active composition from a biofilm
FR3005392B1 (en) * 2013-05-07 2015-09-18 United Pharmaceuticals ANTI-REGURGITATION COMPOSITION PRESERVING INTESTINAL TRANSIT

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102916A (en) * 1990-07-03 1992-04-07 Jacques Antoun Method of relieving gastric ulcers with carob extract
KR20050119134A (en) * 2003-03-21 2005-12-20 넥스메드 홀딩스 인코포레이티드 Prostaglandin compositions for the treatment of erectile dysfunction
US20120282198A1 (en) * 2009-12-24 2012-11-08 Isp Investments Inc. Cosmetic and/or pharmaceutical composition comprising an extract of carob as active agent for activating aquaporin expression
KR20130092499A (en) * 2012-02-10 2013-08-20 주식회사 바이오그랜드 Composition for preventing and improving sex hormone-related disease and symptoms comprising dandelion extract or dandelion containing multiple extract as an active ingredient
KR20140100608A (en) * 2013-02-05 2014-08-18 주식회사 바이오그랜드 Composition for preventing and improving andropause syndrome and aging of male comprising rooibos extract as an active ingredient

Also Published As

Publication number Publication date
JP6430659B2 (en) 2018-11-28
KR101525948B1 (en) 2015-06-05
JP2018500393A (en) 2018-01-11

Similar Documents

Publication Publication Date Title
WO2010134756A2 (en) Composition comprising green tea extract
WO2010058926A2 (en) Pharmaceutical composition containing ginger extract or shogaol
KR101563577B1 (en) Functional composition for improving, preventing hypoestrogenism of women experiencing menopause
WO2018043864A1 (en) Leuconostoc holzapfelii strain having hair loss prevention, hair growth promotion or sexual function improvement effects, and composition comprising same
Yang et al. Schisandra chinensis reverses visceral hypersensitivity in a neonatal–maternal separated rat model
WO2016148545A1 (en) Composition for preventing or improving male menopause symptoms
WO2007083594A1 (en) Laxative and food containing the same
WO2018186557A1 (en) Pharmaceutical composition for preventing or treating andropause syndrome, containing elaeagnus multiflora thunb. extract as active ingredient
WO2016093637A1 (en) Composition for preventing and improving andropause, comprising carob extract as active ingredient
WO2014112676A1 (en) Massage oil for deep sleep
EP2858655A1 (en) Extracts from mother-of-thyme and the use thereof
CN110664847A (en) Application of fecal flora in preparation of microecological preparation for treating chronic hepatitis B
CN104435465A (en) Traditional Chinese medicine composition for treating parkinson disease
WO2009134010A2 (en) Pharmaceutical composition using herbal extract for prevention and treatment of obesity and metabolic disorders
CN107837384A (en) A kind of Chinese medicine composition for treating hand-foot-and-mouth disease
CN108904596B (en) Composition with memory improving effect
CN114158735A (en) Probiotic composition and application thereof
EP4161550A1 (en) Shan-zha for the treatment of depression and anxiety disorders
CN115768417A (en) Muscular atrophy inhibitor
CN111956751A (en) Pharmaceutical composition for treating hyperuricemia and preparation method thereof
WO2005018654A1 (en) Use of enrerococcus faecium strains for curing hepatic insufficiency and for regenerating and intensifying metabolism in a liver
US10413556B1 (en) Production of insulin by testosterone olfaction
CN116159102B (en) Traditional Chinese medicine composition for treating postprandial discomfort syndrome as well as preparation method and application thereof
RU2763761C1 (en) Hepatoprotective humic agent
CN117838829A (en) Traditional Chinese medicine composition for improving inflammation-associated fatigue

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15867462

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017550441

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15867462

Country of ref document: EP

Kind code of ref document: A1